Drug updated on 11/15/2023
|Capsule (oral; 1.34 mg, 0.89 mg)
|Ongoing and Completed Studies
- Indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Product Monograph / Prescribing Information
|Fotivda (tivozanib) Prescribing Information.
|AVEO Pharmaceuticals, Inc. Boston, MA
Systematic Reviews / Meta-Analyses
|Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
|Frontiers in Pharmacology
|Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.
|Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: a systematic review and network meta-analysis of safety.
|Targeted therapy for metastatic renal cell carcinoma.
|Cochrane Database of Systematic Reviews
|Tivozanib for treating advanced renal cell carcinoma.